About Mission

Overview

Mission is the world leader in deubiquitylating enzyme drug discovery and development.

Vision

Our vision is to transform the treatment of serious diseases by targeting disease-associated deubiquitylating enzymes to harness a new class of drugs.

Understanding the complexity of our goal, we focus on areas of significant unmet medical need – disease areas where new therapeutics have the potential to make dramatic improvements in the quality of life and survival of patients.

Patient focused

Mission Therapeutics is determined to make a positive impact on the lives of patients suffering from serious diseases including acute kidney inury (AKI), rare mitochondria diseases, neurodegeneration, and fibrosis by developing first-in-class therapeutics that inhibit disease-associated deubiquitylating enzymes (DUBs).

Why DUBs

DUBs comprise a group of around 100 human proteins that play important roles in regulating ubiquitylation, the process whereby ubiquitin – a small, regulatory protein so called because it is present in all complex organisms and virtually every cell in the body – controls protein homeostasis, protein activity, intracellular location, and sub-cellular turnover or degradation.

World-leading DUB platform

Mission Therapeutics has built a proprietary world-leading DUB platform that combines novel disease biology, bespoke screening tools and unique chemistry, thereby generating a rich pipeline of highly potent and selective small-molecule drug candidates that have substantial clinical and commercial potential. The Company is now progressing several programs towards and into clinical development.

Blue chip investors

To date the Company has received £73 million / $101 million in venture capital from a blue chip syndicate comprising institutional and corporate investors that include: IP Group plc, Schroder Adveq, Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments.

Experienced leadership team

Mission’s leadership team has a wealth of international, commercial and scientific experience. The Company has a collaborative, science-driven culture and has strong collaborations with key academic and research centers. These include the Gurdon Institute Cancer Research UK Laboratories at the University of Cambridge, Oxford Parkinson’s Disease Centre at the University of Oxford, and the Wellcome Trust Mitochondrial Research Centre at Newcastle University.

Location

Founded in 2011, Mission Therapeutics is based at the Babraham Research Campus in Cambridge, UK.

Click here for a tour of our office and labs and to watch BioMed Realty’s grand opening of the Glenn Berge Building, located on Babraham Research Campus. Mission Therapeutics re-located to these new premises in May 2020.

Key Facts

  • List Title 1

    Lorem ipsum dolor sit amet, integre evertitur usu in, sit nonumy detraxit ei. Te placerat interesset vis. Ut nec gubergren

  • List Title 2

    Lorem ipsum dolor sit amet, integre evertitur usu in, sit nonumy detraxit ei. Te placerat interesset vis. Ut nec gubergren

  • List Title 3

    Lorem ipsum dolor sit amet, integre evertitur usu in, sit nonumy detraxit ei. Te placerat interesset vis. Ut nec gubergren

Mission Therapeutics © website by Instinctif Partners